More lawsuits alleging securities fraud were brought against life sciences companies in 2019 than the year before, a new report from law firm Dechert LLP finds. And the near 13% year-over-year increase continues a trend that has seen the number of such suits more than double since 2014.
In total, shareholders brought 97 suits against life sciences companies last year, up from 86 in 2018. Only 39 of these suits were brought in 2014, the first year for which data was available
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?